E7386, Co-Created with Eisai, Shows Efficacy in Hepatocellular Carcinoma Treatment – Publication in Clinical Cancer Research

Published on: December 18, 2025

PRISM BioLab and Eisai Co., Ltd. are pleased to announce that a scientific paper on E7386, co-created by our two companies, has been published in the international medical journal “Clinical Cancer Research.” The paper demonstrates the efficacy of E7386 in combination with lenvatinib mesylate.

For more details, please click here (Japanese language only).